Biosimilars Arrived in Medicare Part D — Spending in Those Categories Didn't Fall
Originator Humira's claim volume fell by more than half between 2018 and 2020. Its cost per claim rose anyway.
That combination is the central puzzle in Medicare Part D's adalimumab data, and it cuts against the foundational assumption behind biosimilar policy: that competition drives prices down. In the adalimumab category, it didn't.
Volume Shifted, But Prices Kept Rising Across the Board
The volume story looks like a success at first glance. Originator Humira went from 70,655 total claims in 2018 to 34,816 in 2020, a drop of more than 50%. Patients and prescribers were clearly moving toward other formulations. The market was responding.
The price story tells something different. Originator Humira's cost per claim rose from $5,916.65 in 2018 to $6,228.13 in 2019 to $6,640.75 in 2020, a 12.2% increase over two years. The products classified as biosimilars followed the same trajectory. Humira Pen (Biosimilar) went from $5,984.87 per claim in 2018 to $6,834.93 in 2020. Humira(Cf) Pen rose from $5,686.69 to $7,117.05 over the same period.
Every major formulation in the adalimumab category got more expensive per claim, even as volume redistributed across them. For Medicare beneficiaries and the program itself, this means the shift away from the originator produced no per-unit savings. The category's cost structure moved in one direction regardless of which product patients received.
The Specialty Tier Problem Is Worse Than the Headline Numbers Suggest
The aggregate figures obscure a sharper problem at the specialty end of the market. In 2019, Humira(Cf) Pen Crohn's-UC-HS carried a cost per claim of $16,096.44. By 2020, Humira(Cf) Pediatric Crohn's reached $17,504.38 per claim, the highest single cost-per-claim figure in the dataset.
These are not high-volume products. But they serve patients with serious conditions, including children with Crohn's disease, where there are few therapeutic alternatives. A cost per claim of $17,504.38 for a pediatric indication means that even a modest number of patients generates substantial program liability, and those patients have essentially no competitive market to protect them.
The broader adalimumab category reached over $2.4 billion in total drug costs in 2018 alone, with the Humira Pen formulation (classified as Biosimilar) accounting for $2,043,354,751 of that across 341,420 claims. That single product line, at a cost per claim of $5,984.87, was already the dominant driver of category spending before any meaningful volume shift had occurred.
What the Adalimumab Case Reveals About Biosimilar Competition
The standard model holds that biosimilar entry creates price competition that benefits payers and patients. The adalimumab data from 2018 to 2020 shows a market where biosimilar-classified products held the majority of claim volume from the start, yet per-claim costs rose across every major formulation.
| Product | 2018 Cost/Claim | 2019 Cost/Claim | 2020 Cost/Claim |
|---|---|---|---|
| Humira (Originator) | $5,916.65 | $6,228.13 | $6,640.75 |
| Humira Pen (Biosimilar) | $5,984.87 | $6,410.90 | $6,834.93 |
| Humira(Cf) Pen (Biosimilar) | $5,686.69 | $6,447.23 | $7,117.05 |
Originator Humira's total drug cost fell from $418,040,620 in 2018 to $231,204,202 in 2020, which looks like savings. But that decline came entirely from lower claim volume, not lower prices. The per-claim cost rose 12.2% while volume fell 50.7%. If the remaining originator claims had been priced at 2018 levels, the program would have spent roughly $23 million less on that product alone in 2020.
Given that originator Humira's cost per claim rose from $5,916.65 in 2018 to $6,640.75 in 2020 even as its claim volume dropped sharply, the formulary and rebate structures governing this category appear to be insulating per-unit prices from the competitive pressure that biosimilar entry was supposed to create.
Ask a follow-up
Run one of these against the same data. The question is filled in for you.
- How has the cost per claim for adalimumab (Humira) changed from 2013 to 2023?
- What are the top 20 specialty drugs by cost per claim in 2020, excluding low-volume drugs with fewer than 1,000 claims?
- Which drug categories have the highest total Part D spending in 2023, and how does adalimumab rank among them?
Explore the data yourself
Run your own queries against 240M+ rows of federal health data using natural language — powered by AI.
Start analyzing